The current research status of the diagnosis and treatment of status epilepticus

doi:10.12092/j.issn.1009-2501.2026.02.005

Abstract

Abstract:

Status epilepticus (SE) is a severe critical condition that poses a great threat to patients. Over the past decade or so, a series of important progress has been made in the research of SE. This article comprehensively refers to the recent domestic and foreign authoritative guidelines, expert consensus, and the latest cutting-edge research results, and describes the latest progress of SE, as well as the current research status of its diagnosis and treatment. It further explores the key challenges faced by SE in current clinical practice and predicts the future development trends, aiming to provide assistance for clinical practice.

Key words: epilepsy, convulsive status epilepticus, non-convulsive status epilepticus

CLC Number:

Youyang QU, Yulan ZHU. The current research status of the diagnosis and treatment of status epilepticus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 175-184.

Figures/Tables 3

References 63

1	Gettings JV, Mohammad Alizadeh Chafjiri F, Patel AA, et al. Diagnosis and management of status epilepticus: improving the status quo[J]. The Lancet Neurology, 2025, 24 (1): 65- 76. doi: 10.1016/S1474-4422(24)00430-7
2	Ascoli M, Ferlazzo E, Gasparini S, et al. Epidemiology and outcomes of status epilepticus[J]. Int J Gen Med, 2021, 14, 2965- 2973. doi: 10.2147/IJGM.S295855
3	Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--report of the ILAE task force on classification of satus epilepticus [J]. Epilepsia, 2015, 56(10): 1515-1523.
4	Trinka E, Leitinger M. Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus[J]. Continuum (Minneapolis, Minn), 2022, 28 (2): 559- 602. doi: 10.1212/CON.0000000000001103
5	Cruickshank M, Imamura M, Counsell C, et al. Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence[J]. J Neurol, 2022, 269 (7): 3420- 3429. doi: 10.1007/s00415-022-10979-2
6	Johnson EL, Kaplan PW. Status epilepticus: definition, classification, pathophysiology, and epidemiology[J]. Semin Neurol, 2020, 40 (6): 647- 651. doi: 10.1055/s-0040-1718722
7	宿英英, 黄旭升, 潘速跃, 等. 惊厥性癫痫持续状态监护与治疗(成人)中国专家共识[J]. 中国现代神经疾病杂志, 2015, 15 (11): 844- 851.
8	Ochoa JG, Dougherty M, Papanastassiou A, et al. Treatment of super-refractory status epilepticus: a review [J]. Epilepsy Curr, 2021, 21(6): 1535759721999670.
9	邓会芳, 孙婧, 王博, 等. 神经重症患者非惊厥性癫痫持续状态的早期预防及分步治疗研究进展[J]. 中国现代医学杂志, 2023, 33 (22): 43- 47.
10	李松林, 方健, 陈文武. 非惊厥性癫痫持续状态临床特点及治疗现状[J]. 河南大学学报(医学版), 2016, 35 (3): 1561- 1571. doi: 10.15991/j.cnki.41-1361/r.2016.03.002
11	孙剑. 脑电监测技术对非惊厥性癫痫持续状态患者的诊断价值[J]. 检验医学与临床, 2019, 16 (18): 2696- 2698.
12	Baker AM, Yasavolian MA, Arandi NR, et al. Nonconvulsive status epilepticus: overlooked and undertreated[J]. Emerg Med Pract, 2019, 21 (10): 1- 24.
13	Peltola ME, Leitinger M, Halford JJ, et al. Routine and sleep EEG: minimum recording standards of the international federation of clinical neurophysiology and the international league against epilepsy[J]. Epilepsia, 2023, 64 (3): 602- 618. doi: 10.1111/epi.17448
14	Sansevere AJ, Hahn CD, Abend NS, et al. Conventional and quantitative EEG in status epilepticus[J]. Seizure, 2019, 68, 38- 45. doi: 10.1016/j.seizure.2018.09.011
15	McKenzie ED, Lim AS, Leung EC, et al. Validation of a smartphone-based EEG among people with epilepsy: a prospective study[J]. Scientific Reports, 2017, 7, 45567. doi: 10.1038/srep45567
16	Richard C, Schriger D, Weingrow D, et al. Rapid electroencephalography and artificial intelligence in the detection and management of nonconvulsive seizures[J]. Ann Emerg Med, 2024, 84 (4): 422- 427. doi: 10.1016/j.annemergmed.2024.04.026
17	Tveit J, Aurlien H, Plis S, et al. Automated interpretation of clinical electroencephalograms using artificial intelligence[J]. JAMA Neurol, 2023, 80 (8): 805- 812. doi: 10.1001/jamaneurol.2023.1645
18	Alkhachroum A, Ganesan SL, Koren JP, et al. Quantitative EEG-based seizure estimation in super-refractory status epilepticus[J]. Neurocritical Care, 2022, 36 (3): 897- 904. doi: 10.1007/s12028-021-01395-x
19	Guerriero RM, Gaillard WD. Imaging modalities to diagnose and localize status epilepticus[J]. Seizure, 2019, 68, 46- 51. doi: 10.1016/j.seizure.2018.10.010
20	Burneo JG, Poon R, Kellett S, et al. The utility of positron emission tomography in epilepsy[J]. Can J Neurol Sci, 2015, 42 (6): 360- 371. doi: 10.1017/cjn.2015.279
21	Sriwastwa A, Trout AT, Mahoney BW, et al. Nuclear medicine imaging in epilepsy[J]. Radiographics, 2025, 45 (1): e240062. doi: 10.1148/rg.240062
22	Barcia Aguilar C, Sánchez Fernández I, Loddenkemper T, et al. Status epilepticus-work-up and management in children[J]. Semin Neurol, 2020, 40 (6): 661- 674.
23	Knowles JK, Helbig I, Metcalf CS, et al. Precision medicine for genetic epilepsy on the horizon: recent advances, present challenges, and suggestions for continued progress[J]. Epilepsia, 2022, 63 (10): 2461- 2475. doi: 10.1111/epi.17332
24	Fisher RS, Chan DW, Bare M, et al. Capillary prolactin measurement for diagnosis of seizures[J]. Ann Neurol, 1991, 29 (2): 187- 190. doi: 10.1002/ana.410290212
25	Abubakr A, Wambacq I. Diagnostic value of serum prolactin levels in PNES in the epilepsy monitoring unit[J]. Neurol Clin Pract, 2016, 6 (2): 116- 119. doi: 10.1212/CPJ.0000000000000232
26	Wang YQ, Wen Y, Wang MM, et al. Prolactin levels as a criterion to differentiate between psychogenic non-epileptic seizures and epileptic seizures: a systematic review[J]. Epilepsy Res, 2021, 169, 106508. doi: 10.1016/j.eplepsyres.2020.106508
27	Margraf NG, Dargvainiene J, Theel E, et al. Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus[J]. J Neurol, 2023, 270 (4): 2128- 2138. doi: 10.1007/s00415-022-11547-4
28	Hanin A, Denis J A, Frazzini V, et al. Neuron specific enolase, S100-beta protein and progranulin as diagnostic biomarkers of status epilepticus[J]. J Neurol, 2022, 269 (7): 3752- 3760. doi: 10.1007/s00415-022-11004-2
29	Liu YH, Cheng YT, Tsai MH, et al. Genetics and clinical correlation of dravet syndrome and its mimics - experience of a tertiary center in Taiwan[J]. Pediatr Neonatol, 2021, 62 (5): 550- 558. doi: 10.1016/j.pedneo.2021.05.022
30	Kienitz R, Kay L, Beuchat I, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability[J]. CNS Drugs, 2022, 36 (9): 951- 975. doi: 10.1007/s40263-022-00940-2
31	Niquet J, Lumley L, Baldwin R, et al. Rational polytherapy in the treatment of cholinergic seizures[J]. Neurobiol Dis, 2020, 133, 104537. doi: 10.1016/j.nbd.2019.104537
32	Joshi S, Rajasekaran K, Hawk KM, et al. Status epilepticus: role for etiology in determining response to benzodiazepines[J]. Ann Neurol, 2018, 83 (4): 830- 841. doi: 10.1002/ana.25213
33	Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus[J]. N Engl J Med, 2001, 345 (9): 631- 637. doi: 10.1056/NEJMoa002141
34	Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus[J]. N Engl J Med, 1998, 339 (12): 792- 798. doi: 10.1056/NEJM199809173391202
35	Burman RJ, Raimondo JV, Jefferys JGR, et al. The transition to status epilepticus: how the brain meets the demands of perpetual seizure activity[J]. Seizure, 2020, 75, 137- 144. doi: 10.1016/j.seizure.2019.09.012
36	Sánchez Fernández I, Goodkin HP, Scott RC, et al. Pathophysiology of convulsive status epilepticus[J]. Seizure, 2019, 68, 16- 21. doi: 10.1016/j.seizure.2018.08.002
37	Walker MC. Pathophysiology of status epilepticus[J]. Neurosci Lett, 2018, 667, 84- 91. doi: 10.1016/j.neulet.2016.12.044
38	Pironi V, Ciccone O, Beghi E, et al. Survey on the worldwide availability and affordability of antiseizure medications: report of the ILAE task force on access to treatment[J]. Epilepsia, 2022, 63 (2): 335- 351. doi: 10.1111/epi.17155
39	Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults[J]. Epilepsy Curr, 2016, 16 (1): 48- 61. doi: 10.5698/1535-7597-16.1.48
40	Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus[J]. N Engl J Med, 2019, 381 (22): 2103- 2113. doi: 10.1056/NEJMoa1905795
41	Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT)[J]. Lancet, 2019, 393 (10186): 2135- 2145. doi: 10.1016/S0140-6736(19)30722-6
42	Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE)[J]. Lancet, 2019, 393 (10186): 2125- 2134. doi: 10.1016/S0140-6736(19)30724-X
43	Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT)[J]. Lancet, 2020, 395 (10231): 1217- 1224. doi: 10.1016/S0140-6736(20)30611-5
44	Husain AM, Lee JW, Kolls BJ, et al. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures[J]. Ann Neurol, 2018, 83 (6): 1174- 1185. doi: 10.1002/ana.25249
45	Sánchez Fernández I, Gaínza-Lein M, Lamb N, et al. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus[J]. Neurology, 2019, 92 (20): e2339- e2348. doi: 10.1212/wnl.0000000000007503
46	Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults[J]. Eur J Neurol, 2010, 17 (3): 348- 355. doi: 10.1111/j.1468-1331.2009.02917.x
47	Der-Nigoghossian C, Tesoro EP, Strein M, et al. Principles of pharmacotherapy of seizures and status epilepticus[J]. Semin Neurol, 2020, 40 (6): 681- 695. doi: 10.1055/s-0040-1718721
48	Aleyadeh R, Carson RP. Fosphenytoin [M]. Treasure Island (FL): StatPearls Publishing LLC, 2025.
49	Nakamura K, Marushima A, Takahashi Y, et al. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus[J]. J Neurol Neurosurg Psychiatry, 2023, 94 (1): 42- 48. doi: 10.1136/jnnp-2022-329485
50	Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy[J]. Epilepsia Open, 2018, 3 (2): 175- 192.
51	Kirmani BF, Au K, Ayari L, et al. Super-refractory status epilepticus: prognosis and recent advances in management[J]. Aging Dis, 2021, 12 (4): 1097- 1119. doi: 10.14336/AD.2021.0302
52	Jacobwitz M, Mulvihill C, Kaufman MC, et al. Ketamine for management of neonatal and pediatric refractory status epilepticus[J]. Neurology, 2022, 99 (12): e1227- e1238. doi: 10.1212/wnl.0000000000200889
53	Dhir A, Chopra K. Memantine delayed N-methyl-D-aspartate-induced convulsions in neonatal rats[J]. Fundam Clin Pharmacol, 2015, 29 (1): 72- 78.
54	Moalong KMC, Espiritu AI, Fernandez MLL, et al. Efficacy and tolerability of intravenous brivaracetam for status epilepticus[J]. J Neurol Sci, 2020, 413, 116799. doi: 10.1016/j.jns.2020.116799
55	Sutula TP, Fountain NB. 2DG and glycolysis as therapeutic targets for status epilepticus[J]. Epilepsy Behav, 2023, 140, 109108. doi: 10.1016/j.yebeh.2023.109108
56	Shrestha N, Khan S, Neupane YR, et al. Tailoring midazolam-loaded chitosan nanoparticulate formulation for enhanced brain delivery via intranasal route[J]. Polymers, 2020, 12 (11): 2567.
57	Nair SC, Vinayan KP, Mangalathillam S, et al. Nose to brain delivery of phenytoin sodium loaded nano lipid carriers[J]. Pharmaceutics, 2021, 13 (10): 1623.
58	赵明雪, 刘世光, 范美丽, 等. 33例儿童癫痫持续状态的临床特点及预后影响因素分析[J]. 癫痫杂志, 2022, 8 (1): 48- 51.
59	Der-Nigoghossian C, Rubinos C, Alkhachroum A, et al. Status epilepticus - time is brain and treatment considerations[J]. Curr Opin Crit Care, 2019, 25 (6): 638- 646. doi: 10.1097/mcc.0000000000000661
60	Dibué-Adjei M, Brigo F, Yamamoto T, et al. Vagus nerve stimulation in refractory and super-refractory status epilepticus[J]. Brain Stimul, 2019, 12 (5): 1101- 1110. doi: 10.1016/j.brs.2019.05.011
61	Hawkes MA, Hocker SE. Systemic complications following status epilepticus[J]. Curr Neurol Neurosci Rep, 2018, 18 (2): 7. doi: 10.1007/s11910-018-0815-9
62	Soliman N, Alsultan M, Alhusseini A, et al. Status epilepticus resulted in rhabdomyolysis-induced AKI associated with hepatotoxicity[J]. Medicine, 2024, 103 (8): e36834. doi: 10.1097/MD.0000000000036834
63	Bravo P, Vaddiparti A, Hirsch LJ, et al. Pharmacotherapy for nonconvulsive seizures and nonconvulsive status epilepticus[J]. Drugs, 2021, 81 (7): 749- 770. doi: 10.1007/s40265-021-01502-4

分类标准	类型		定义
分类标准	类型		T1 （可能导致持续发作时间）	T2 （可能导致长期后果时间）
根据癫痫发作持续时间及发作长期后果分类	强直阵挛性癫痫发作		5 min	30 min
	伴意识障碍的局灶性癫痫发作		10 min	>60 min
	失神状态癫痫持续状态		10～15 min	未知
根据癫痫发作持续时间和治疗反应分类	早期或可能的癫痫持续状态		持续或间歇性癫痫发作，持续时间超过5 min，发作间期无意识恢复
	确诊癫痫持续状态		对一线苯二氮?类药物治疗无反应的癫痫发作
	难治性癫痫持续状态		使用两种足够剂量抗癫痫药物（如一线苯二氮?类药物+ 二线非苯二氮?类）后仍持续发作
	超难治性癫痫持续状态		使用麻醉剂治疗，难治性癫痫持续状态仍持续超过24 h或在撤机麻醉后复发的难治性癫痫持续状态
	特定综合征	NORSE	无癫痫病史或明确病因的患者突发难治性癫痫持续状态
	特定综合征	FIRES	儿童在发热性感染后急性发作难治性癫痫持续状态，伴认知功能损害

分类标准	类型		定义
分类标准	类型		T1 （可能导致持续发作时间）	T2 （可能导致长期后果时间）
根据癫痫发作持续时间及发作长期后果分类	强直阵挛性癫痫发作		5 min	30 min
	伴意识障碍的局灶性癫痫发作		10 min	>60 min
	失神状态癫痫持续状态		10～15 min	未知
根据癫痫发作持续时间和治疗反应分类	早期或可能的癫痫持续状态		持续或间歇性癫痫发作，持续时间超过5 min，发作间期无意识恢复
	确诊癫痫持续状态		对一线苯二氮?类药物治疗无反应的癫痫发作
	难治性癫痫持续状态		使用两种足够剂量抗癫痫药物（如一线苯二氮?类药物+ 二线非苯二氮?类）后仍持续发作
	超难治性癫痫持续状态		使用麻醉剂治疗，难治性癫痫持续状态仍持续超过24 h或在撤机麻醉后复发的难治性癫痫持续状态
	特定综合征	NORSE	无癫痫病史或明确病因的患者突发难治性癫痫持续状态
	特定综合征	FIRES	儿童在发热性感染后急性发作难治性癫痫持续状态，伴认知功能损害

[1]	Yiling CHEN, Guoxing ZHU. Advances in pharmacotherapy for adult epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 146-153.
[2]	Tianshuang WANG, Xinhua WANG, Yuanfeng ZHOU. Advances in pharmacotherapy for pediatric epilepsy syndromes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 154-161.
[3]	Zhengqing ZHAO, Yanpeng LI, Zhongxin ZHAO. Clinical characteristics and medicine treatment progress in female patients with epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 162-167.
[4]	Feifei ZHAI, Yan HUANG. Diagnosis and management of sleep-related hypermotor epilepsy: an update [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 168-174.
[5]	ZHAO Yahong, LI Qiang . Targeting ferroptosis offers a novel therapeutic approaches in epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(6): 828-834.
[6]	CHEN Sirui, LI Junqiang, DANG Xiaoli, WANG Tiancheng. Progress in researches for perampanel in the treatment of comorbidities of epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(3): 354-360.
[7]	LI Chenhao, YU Xihua, YAN Wenhao, CHAI Yuxia, LI Yanyan, LI Kun, LI Zeyun. Research progress on the relationship between pediatric epilepsy and vitamin D [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1299-1306.
[8]	DANG Yangbin, LIANG Yuxin, WANG Tiancheng. Research progress on the related treatment of progressive myoclonic epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1184-1194.
[9]	YAN Yukui, HU Jianqin, ZHANG Bing. Clinical study of new and conventional antiepileptic drugs with newly diagnosed partial epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 793-799.
[10]	WANG Ting, HAN Mingming, LI Juan. Effect of dexmedetomidine on muscle relaxant effect of cisatracurium in patients with epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1113-1118.
[11]	TAO Huai, XU Lujiadai, CHEN Xia. Occurrence and clinical treatment of epilepsy associated with gene mutation in voltagegated sodium channel subtypes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 570-577.
[12]	ZENG Xiangchang, ZHOU Luping, CHEN Lulu, LUO Wei, LI Chaopeng, GAO Qing, WANG Yaqin, WANG Xintong, HU Kai, SHEN Jie, OUYANG Dongsheng. Effects of ginsenoside C-K on seizure activity in pilocarpine-induced epileptic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 139-143.
[13]	NI Hong, ZHENG Bu-zhen, WANG En, JIN Xiao-ping, MA Chuan-hua, KE Shao-fa, ZHOU Yuan-lin, CHU Zhao-hu. Study of GABAergic neurons electrophysiological changes after levetiracetam intervention in the epileptic mouse hippocampal [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 505-509.
[14]	TANG Zhi-hua, ZHANG Ke-ying, XIAO Xing-feng. Analysis of the monitoring results and the influencing factors of blood concentration of valproate in patients with epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 1051-1055.
[15]	BAI Xiang-rong, JIANG De-chun, WANG Yu-qin, QI Xiao-lian. Effects of CYP2C19 and CYP2C9 genotype on valproate clearance in patients with epilepsy in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1405-1410.